Invex Therapeutics Ltd (ASX:IXC)
Australia · Delayed Price · Currency is AUD 0.1100
0.00 (0.00%)
At close: Oct 6, 2026
Invex Therapeutics Market Cap
Invex Therapeutics has a market cap or net worth of 8.27 million as of October 8, 2026. It is the 44,414th most valuable company in the world and the 1,410th biggest in Australia. Its market cap has decreased by 8.33% in one year.
Market Cap
8.27M
Enterprise Value
4.25M
Revenue
46.83K
Global Rank
Country Rank
#1,410 Australia
PE Ratio
n/a
ChartMarket Cap Chart
Since July 5, 2019, Invex Therapeutics's market cap has decreased from 59.13M to 8.27M, a decrease of -86.02%. That is a compound annual growth rate of -23.74%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 6, 2026 | 8.27M | -8.33% |
| Dec 30, 2025 | 9.02M | 81.82% |
| Dec 23, 2024 | 4.96M | -18.52% |
| Dec 27, 2023 | 6.09M | -85.14% |
| Dec 28, 2022 | 40.96M | -22.70% |
| Dec 31, 2021 | 52.98M | -1.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jul 5, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| EZZ Life Science Holdings | 16.47M |
| Cambium Bio | 15.89M |
| ReNerve | 14.99M |
| Immuron | 14.53M |
| AdAlta | 11.24M |
| Bio-Gene Technology | 7.01M |
| Vectus Biosystems | 6.53M |
| Acrux | 6.49M |